Tibet Cheezheng subsidiary gets clinical trial nod for pediatric drug

Tibet Cheezheng Tibetan Medicine Co., Ltd. (SZSE:002287) announced that its subsidiaries, Qizheng (Zhuhai Hengqin) International Pharmaceutical Co., Ltd. and Gansu Qizheng Tibetan Medicine Co., Ltd., have received a clinical trial approval notice from the National Medical Products Administration for their drug, "Xiao'er Relique Granules" (小儿热立清颗粒). This drug is a Class 1.1 traditional Chinese medicine innovation targeting acute upper respiratory tract infections characterized by wind-heat and dampness in children. The approval allows the company to proceed with Phase II and Phase III clinical trials, marking a significant step in the drug's development. While this progress may enhance the company's position in the pediatric pharmaceutical sector, the announcement noted that the drug's actual impact on company performance will depend on future development and market factors.